An observational study in Atopic Dermatitis, sponsored by Sanofi. Active, not recruiting at 42 sites in France. Open to participants aged 6 Years and older. Per ClinicalTrials.gov, last updated 2026-11-19.
Sponsored by Sanofi · Observational
How we know · 3 judgments
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 43 studies in Dermatitis, Atopic by Sanofi — 5 open to participants now, 16 under way, 4 of them phase 3. Dermatitis, Atopic · Sanofi.
Among the 43 studies in Dermatitis, Atopic by Sanofi, this one is the 7th largest by enrollment of the 15 observational ones that give a count, is one of 10 that started in 2023, is one of 15 observational ones, reaches primary completion later than 11 of the 15 other live ones, and was the 30th registered.
1,596 studies on the registry are indexed under Dermatitis, Atopic; 289 are open to participants now.
Browse Dermatitis, Atopic studies →5 of the 43 studies in Dermatitis, Atopic by Sanofi are open now, in 10 countries. Recruiting first, the newest first:
Sanofi · Sites in Qatar, Saudi Arabia, United Arab Emirates
Ages 12+
Sanofi · Sites in United States, Canada, China and 6 more countries
Ages 12+
Sanofi · Sites in Italy
Ages 6 mo–17 yrs
Sanofi
Ages 12+
Sanofi
Ages 18+
By country, each count listing its studies:
Of the 195 Dermatitis, Atopic studies recruiting now, 84 (43%) set no upper age limit and 95 (49%) stop at 75 or younger; 94 take children under 18; 52 take healthy volunteers.
This study: 6 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
43 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 10 · Phase 3 10 · Phase 4 8
First in 2006; this study’s year is marked. 10 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 303 is above the median of 150 across 284 observational studies indexed under Dermatitis, Atopic.
Median enrollment 112 across the 28 interventional studies, 266 across the 15 observational. Of the 26 that completed or were terminated, 9 (35%) have results posted.
This tab as a report to print or save as PDF → With an account.
Sanofi is the lead sponsor of 1,560 studies on the registry; 90 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 123 (60%) have results posted.
6 of the studies in Dermatitis, Atopic by Sanofi that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06241118Phase 3SanofiA Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab on Background Topical Corticosteroids Therapy in Participants Aged 12 Years and Older With Moderate-to-severe AD Who Have Had an Inadequate Response to Prior Biologic Therapy or an Oral JAK Inhibitor | 2027-09-30 |
| NCT07905547SanofiA Study to Investigate Dupixent/ Dupilumab in Adult Indian Participants With Moderate-to-severe Atopic Dermatitis | 2027-02-07 |
| NCT03992417SanofiObservational Study of Patients Receiving Dupixent® for Atopic Dermatitis (AD) | 2027-03-31 |
| NCT05983068SanofiA Study of Long-term Effect of Dupilumab on Skin Barrier Function in Pediatric Participants With Atopic Dermatitis | 2027-04-29 |
| NCT06837454SanofiFrench Prospective Observational Study in Patients Eligible for Systemic Therapy for Atopic Dermatitis (AD) | 2027-05-13 |
Add all 6 to your calendar (.ics) → With an account.
Among the 43 studies in Dermatitis, Atopic by Sanofi, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a long-term study to collect data over 3 years in order to find out what is likely to happen in the future regarding participants 6 years of age and older who receive dupilumab for Atopic Dermatitis (AD) commonly known as Eczema, and to characterize real-world effectiveness, safety and use patterns of dupilumab in real world setting in France. Patients will be invited to participate if initiating treatment with dupilumab for AD according to French-specific prescribing information. The decision of initiation of the treatment is independent to the study's participation. The study will be conducted in approximately 50 centers in France to evaluate a representative sample of patients treated in France. At each participating site, all AD participants who receive an initial prescription for dupilumab will be invited to participate in this study, until the enrollment goal is achieved.
The population of interest for this study will be patients in France aged 6 years old or more with a diagnosis of AD either severe or moderate to severe (depending on age group) who initiate dupilumab in real world setting. The study will be conducted in real conditions of practice, dupilumab will be prescribed at the sole initiative of the participating physician irrespective of patient enrolment decision.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients ≥6 years of age in whom dupilumab therapy was initiated to treat their AD according to French-specific prescribing information.
Drug: Dupilumab
Dupilumab cohort
Also known as: SAR231893, Dupixent®
Demographic characteristics of participants who receive dupilumab for AD
Including age, gender, educational level, socio-professional category
Time frame: At baseline
Weight characteristics of participants who receive dupilumab for AD
Time frame: At baseline
Height characteristics of participants who receive dupilumab for AD
Time frame: At baseline
Medical history characteristics of participants who receive dupilumab for AD
including previous treatments for AD, relevant medical history, family history of atopy
Time frame: At baseline
Comorbidities and treatments change from baseline
Time frame: At baseline, month 3, month 6, month 12, month 18, month 24, month 30, month 36
Atopic comorbidities and treatments change from baseline
Time frame: At baseline, month 3, month 6, month 12, month 18, month 24, month 30, month 36
Change from baseline in lifestyle habits of participants who receive dupilumab for AD
Including alcohol, tobacco, CBD and cannabis consumption
Time frame: At baseline, month 3, month 6, month 12, month 18, month 24, month 30, month 36 if applicable
Change from baseline in dupilumab dose
Time frame: At baseline, month 3, month 6, month 12, month 18, month 24, month 30, month 36
Change from baseline in dupilumab administration
Time frame: At baseline, month 3, month 6, month 12, month 18, month 24, month 30, month 36
Change from baseline in dupilumab compliance with treatment
Time frame: At baseline, month 3, month 6, month 12, month 18, month 24, month 30, month 36
Change from baseline in dupilumab temporary or permanent discontinuation
Time frame: At baseline, month 3, month 6, month 12, month 18, month 24, month 30, month 36
Change from baseline in dupilumab treatment switch to another therapy
Time frame: At baseline, month 3, month 6, month 12, month 18, month 24, month 30, month 36
Change from baseline in dupilumab treatment for concomitant AD treatments
Time frame: At baseline, month 3, month 6, month 12, month 18, month 24, month 30, month 36
Change in patient's treatment satisfaction score using the Patient Global Assessment of Treatment Effect (PGATE)
PGATE for patients ≥ 12 years of age: an internally developed and validated instrument allowing patients to rate their opinion and perceived treatment effect. Ratings are on a 5-point Likert scale from 1 being "Poor" and 5 being "Excellent".
Time frame: At month 6, month 12, month 18, month 24, month 30, month 36
Change in eczema severity using the Eczema Area and Severity Index (EASI)
EASI is a validated measure used to assess severity and extent of AD at each body region by multiplying the lesions characteristics score x the body area score x multiplier. Four AD disease characteristics -erythema, thickness (induration, population, and oedema), scratching (excoriation), and lichenification - will each be assessed for severity by the observing physician, as follows: 0 = none, absent; 1=mild (just perceptible); 2=Moderate (obvious); 3=Severe. The area score ranges from 0 to 6 is determined as follows: 0= 0% (no active eczema in region); 1= 1-9%; 2= 10-29%; 3= 30-49%; 4= 50-69%; 5= 70-89%; 6= 90-100% (entire region affected by eczema). The multiplier is determined according to the region affected and the age of the patient: 0.1 or 0.2 for patients \< 8 years old (head/neck), 0.2 (upper limbs), 0.3 (trunk), 0.4 or 0.3 for patients \< 8 years old (lower limbs). A higher score means higher AD severity. Scores range from 0 (no disease) to 72 (maximal disease severity).
Time frame: At baseline, month 6, month 12, month 18, month 24, month 30, month 36
Change in AD disease control using the Atopic Dermatitis Control Tool (ADCT)
ADCT for patients aged ≥ 12 years of age: a validated, brief and easily scored tool consisting of six concise questions allowing to rate the different dimensions of patient-perceived AD control, to foster communication between patients and their physicians and help appropriate decision-making. The instrument includes 6 items, with a 7-day recall period: overall severity of symptoms, frequency of intense episodes of itching, severity of bother, frequency of sleep impact, severity of daily activities impact and severity of mood or emotions impact. Each item is rated on a 5-point Likert scale, ranging from 0 (none/ not at all/ no nights) to 4 (very severe/ everyday/ extremely/ every night); the total score ranges from 0 to 24, which is the summation of the responses to all the items. A total score of ≥7 points was derived as the threshold to identify patients "not in control", based on optimal sensitivity/ specificity values. The higher the score, the less AD is controlled.
Time frame: At baseline, month 6, month 12, month 18, month 24, month 30, month 36
Change in itch assessment
Itch assessment (Worst-Itch Numeric Rating Scale, WI-NRS) will be rated from 0 to 10 on average during the past 7 days (adult, pediatric and adolescent patients), completed by the observing physician after questioning of patient; 0 = no itch and 10 = the worst imaginable itch.
Time frame: At baseline, month 6, month 12, month 18, month 24, month 30, month 36
Change in sleep disturbance NRS
NRS sleep disturbance will be rated from 0 to 10 on average during the past 7 days (adult, pediatric and adolescent patients), completed by the observing physician after questioning of patient; 0 = "sleep not disturbed at all" (best possible sleep) and 10 = "sleep extremely disturbed (worst possible sleep)".
Time frame: At baseline, month 6, month 12, month 18, month 24, month 30, month 36
Change in global patient's disease evaluation using the Patient Global Assessment of Disease Severity (PGADS)
PGADS for patients ≥ 12 years of age: an internally developed and validated instrument allowing to the patients to rate their AD-related overall well-being. Patients will be asked: "Considering all the ways in which your eczema affects you, how well are you doing?" Response choices will be from 1 being "Poor" to 5 being "Excellent".
Time frame: At baseline, month 6, month 12, month 18, month 24, month 30, month 36
Change in global patient's disease evaluation using the Caregiver Global Assessment of Disease (CGAD)
CGAD for patients 6 to 11 years of age: an internally developed and validated instrument allowing to the caregivers to rate their child's AD-related overall well-being. Caregivers will be asked: "Considering all the way in which the eczema affects your child, how well is your child doing?". Response choices will be 1 being "Poor" to 5 being "Excellent".
Time frame: At baseline, month 6, month 12, month 18, month 24, month 30, month 36
Change in Dermatology Life Quality Index (DLQI)
DLQI for patients ≥ 16 years (or cDLQI for patients \< 16 at baseline) are 10-item, validated questionnaire used in clinical practice and clinical trials to assess the impact of AD disease symptoms and treatment on quality of life in adults and pediatrics, respectively. The format is a simple response (0 to 3 where 0 is "not at all" and 3 is "very much") to 10 items, which assess quality of life over the past week, with an overall scoring system of 0 to 30; a high score is indicative of a poor quality of life. Patients 6-11 years old will be assisted for questionnaire completion. A cDLQI's cartoon version could be also used for patients from 6 to 11 years old. If a patient turns 16 years old during the study, they will switch to DLQI.
Time frame: At baseline, month 6, month 12, month 18, month 24, month 30, month 36
Change in Dermatitis Family Impact Questionnaire (DFI)
DFI is a 10-item, validated questionnaire assessing the impact of AD on the QoL of the parents/legal representatives and family members of affected children. The format is a simple response (0 to 3 where 0 is "not at all" and 3 is "very much") to 10 items, which assess Quality of Life (QoL) over the past week, with an overall scoring system of 0 to 30; a high score is indicative of a poor QoL. It is designed to be completed by adults (aged 16 years or over) who have a child (up to and including the age of 15 years 11 months) in the family with atopic dermatitis.
Time frame: At baseline, month 6, month 12, month 18, month 24, month 30, month 36
Change in European Quality of Life-5 Dimensions-3 level score (EQ-5D-3L)
The EQ-5D-3L is completed by patients≥18 years old and by parent/legal representative of patients\<18 years old. It consists of 2 parts: * The EQ-5D descriptive system has five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each has 3 levels: no problems, some problems, and extreme problems. The patient selects the most appropriate statement in each of the five dimensions, resulting in a 1-digit number for each dimension. The digits for the five dimensions can be combined into a 5-digit number that describes the patient's health state. * The EQ VAS records the patient's self-rated health on a vertical visual analogue scale where the endpoints are labelled 'Best imaginable health state' and 'Worst imaginable health state'. The VAS can be used as a quantitative measure of health outcome that reflects the patient's own judgement. The scale is numbered 0 to 100. A higher value represents better health and a lower value represents worse health.
Time frame: At baseline, month 6, month 12, month 18, month 24, month 30, month 36
Change in Work Productivity and Activity Impairment Questionnaire, Atopic Dermatitis (WPAI-AD)
WPAI-AD for adults and WPAI-CIQ-AD for adolescents is a questionnaire designed to assess the impact of AD on the patient's productivity. The WPAI-AD is the version of the original generic WPAI that is specific to AD. It is a 6-item, validated questionnaire to measure impairments in work and activities over a 7-day recall period. The WPAI-AD outcomes are expressed as impairment percentages, with higher numbers indicating greater impairment and less productivity. If a patient turns 18 years old during the study, this one will switch to WPAI-AD.
Time frame: At month 6, month 12, month 18, month 24, month 30, month 36
Number of Adverse Events (AE)
AEs for dupilumab and/or concomitant treatments will be collected throughout the study.
Time frame: At baseline, month 3, month 6, month 12, month 18, month 24, month 30, month 36
Change from baseline in Drug Survival
Drug survival is defined as the time from the start of treatment to the end or discontinuation of treatment with no changes. If a patient has multiple drug survival events for the same treatment, the longest drug survival will be used in the data summarization. The drug survival will be illustrated using a Kaplan-Meier plot.
Time frame: At baseline, month 3, month 6, month 12, month 18, month 24, month 30, month 36
Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org
No publications or documents are linked to this record.
Started Nov 2023 (actual). Primary completion is estimated for Jul 2028, 55 months after the start.
Of 74 industry-sponsored observational studies under Dermatitis, Atopic, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 84. This study's planned 55 months is above that.
Counting every sponsor, half of 172 studies reached it within 47 months; a quarter within 17.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 19, 2026: primary completion May 2028 → Jul 2028 and completion May 2028 → Jul 2028.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.